Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Says No To “Fee-For-Service” Contracts; Cardinal, Eisai Reach Deal

Executive Summary

Pfizer is not involved in "fee-for-service" negotiations with wholesalers, the company declared in its fourth quarter earnings release Jan. 19

You may also be interested in...



Drug Inventory Workdowns To Continue Through 2005, ABC Says

AmerisourceBergen expects pharmaceutical manufacturer inventory destocking observed during the first quarter of 2005 to continue through the year

Drug Inventory Workdowns To Continue Through 2005, ABC Says

AmerisourceBergen expects pharmaceutical manufacturer inventory destocking observed during the first quarter of 2005 to continue through the year

Rx Wholesalers Responding To Subpoenas On Deals With “Secondary” Market

AmerisourceBergen, Cardinal Health and McKesson are responding to subpoenas from the New York Attorney General's office regarding their use of "secondary" wholesalers as a source of pharmaceuticals

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel